cklee88
Posted - 1 hour ago
$IOBT @Notnotshort , how confident you are with the team? How high is the probability of success, per your estimate?! Problem with this stock is no option to hedge....
Notnotshort
Posted - 3 hours ago
$IOBT Side effect profile is an important factor especially for patients. If you see grade 3/4 events in immunotherapy it means that you have to intervene with immunosuppressive treatments and stop current treatment. anti-TNF treatment basically blocks an important way of killing of cancer cells. So, u not only stop treatment, you might also indirectly enhance tumor growth by adding immunosuppressive drugs. IOBTs goal is to become the backbone of immunotherapy in cancer. How? The vaccine doesnt add systemic toxicities, so no additional interventions that require to stop treatment or use immunosuppressive treatment. They use needles, which might become an issue for a few patients, but thats it. They could add their vax to opduolag without additional systemic toxicities, but they need to first show in the PH3 that the vax adds significant efficacy. The future of cancer treatment is combo/tripple treatments.
Notnotshort
Posted - 1 day ago
$IOBT 42% of patients had stage M1c, vs 60% in IOBTs trial. Higher stages mean increased number of metastases, that results in sicker patients and lower response rate from treatment. 33% of patients in IOBTs trial had liver metastases. We dont know how many liver metastases in the opdualag trial were. DO you know that? Tell us if you know. So, now that we know that patient characteristics are fundamentally different, why do you compare these results?
Notnotshort
Posted - 1 day ago
$IOBT @cklee88 is pumping out false information like always. Gonna educate him. 1) opduolag mPFS 10,1 months. 2)management is garbage, agreed on that. 3) Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients in the relatlimab–nivolumab group and in 9.7% of patients in the nivolumab group. 4) 14,6% of opduolag left trial due to treatment related adverse events vs 3,1% in the nivo group. Higher toxicity hits older, more fragile and sicker patients the most, cause they have the most difficulties dealing with the side effects. So those with the worst chances drop out, becauase they cant deal with the side effects. therefore you will almost always have a benefit from that in the experimental arm, because the fitter, stronger and healthier patients deal better with side effects. Higher toxicity usually has higher efficacy, but the side effects might become an issue. If you can deal with the side effects, you benefit. https://www.nejm.org/doi/full/10.1056/NEJMoa2109970
cklee88
Posted - 1 day ago
$IOBT bearish points: 1) opduolag mPFS 28.5mth vs io 25.5 mths! 2) management isn't good enough in push price up!
cklee88
Posted - 1 day ago
$IOBT opduolag sales in Q1 2024 was 206mio or 25% of 1L melanoma market, per BMY QTR pr. Therefore, total market is about 800mio/ year. If io102-103 can get 10% share then yearly sales is 80mio. This may translate into 800mio market cap, ,~8x from now of usd12. How it go down to between 1.2-1.33, will buy.
Stock_Titan
Posted - 3 days ago
$IOBT IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
https://www.stocktitan.net/news/IOBT/io-biotech-announces-abstract-accepted-for-presentation-at-the-2024-b0yezmb47pij.html
RallyRaider
Posted - 5 days ago
$IOBT calm before the storm
DannyTrejoTrades
Posted - 1 week ago
$IOBT Serious question: Is IOBT going back to $1 or even under $1? If it does, would it be worth taking a position there?
axelvento999
Posted - 2 weeks ago
$IOBT Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committee
RallyRaider
Posted - 2 weeks ago
$IOBT "A quick clarification on what exactly a cancer vaccine is. This is not a shot in the arm that is going to prevent any random person from ever getting disease—although that would certainly be nice. Kopetz describes the cancer vaccines that are coming through the clinic now as an adjuvant treatment that can spur a T-cell response. [...] Cancer vaccines were the talk of oncology meetings like AACR years ago, but Kopetz said the technology just wasn’t ready. Companies ran into issues generating an effective T-cell response and then turning that into a benefit."
RallyRaider
Posted - 2 weeks ago
$IOBT https://www.fiercebiotech.com/biotech/aacr-24-cancer-vaccines-get-reintroduction-technology-finally-comes-together this one is under the radar Remember CEO Zocca repeat "overwhelmingly positive" like 15 times on call.
Stock_Titan
Posted - 2 weeks ago
$IOBT IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
https://www.stocktitan.net/news/IOBT/io-biotech-presents-new-data-at-aacr-2024-further-supporting-dual-znd7d4b9kwgf.html
Streetbullx2
Posted - 1 month ago
$AKBA i live in miami beach, today i get miami beach drunk. paytience is key when the science is outstanding next $CLRB $IKNA $IOBT PDSB TPST CKPT
Streetbullx2
Posted - 1 month ago
$AKBA me tomorrow and in the future with my next quality plays $CLRB $PDSB $IKNA $IOBT
Streetbullx2
Posted - 1 month ago
$AKBA now you can move in with your moms , shorts. tomorrow we bank. get in early when you know ve done the DD and everything checks out. next for me is $IKNA $IOBT $CKPT $CLRB and of course ADAP AND PDSB
Stocks4thought
Posted - 1 month ago
$IOBT DOPE
Jumpytermite
Posted - 1 month ago
$IOBT if not for this POS, all of my bios would be in the green
Stocks4thought
Posted - 1 month ago
$ONCY Hippies makes fortunes- shareholders get his under wear in Australia and toking bong? $IOBT would seem to be a much better horse!!
RallyRaider
Posted - 1 month ago
$IOBT held back by someone-- is on track for high volume day.. breakout imminent
RallyRaider
Posted - 1 month ago
$IOBT they are figuring it out-- this one is very undervalued. 368 watchers and no love... YET
Stock_Titan
Posted - 1 month ago
$IOBT IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
https://www.stocktitan.net/news/IOBT/io-biotech-announces-acceptance-of-abstract-to-be-presented-at-the-ahcoes1hyczq.html
RallyRaider
Posted - 1 month ago
$IOBT Ms Zocca is "very excited" (said it like 10 times) to share further data reminds me of $PASG around 0.80 when asked "what is the biggest risk to ph3" she stutters then says "ehh im just really excited with what we have" check new CMO background, Zocca says he comes in really handy at the moment https://www.linkedin.com/in/dr-qasim-iftikhar-ahmad-7b848a1/
RallyRaider
Posted - 1 month ago
$IOBT please also check comments in newest presentation on TAM and KOL opinions
RallyRaider
Posted - 1 month ago
$IOBT on the third day He rose again....
Skichic
Posted - 1 month ago
$IOBT they have enough cash on hand to fund their operations into the 4th quarter of 2025!
DonCorleone77
Posted - 1 month ago
$IOBT IO Biotech reports Q4 EPS (40c), consensus (39c) "In 2023, we reached a significant milestone in our pivotal Phase 3 trial evaluating our lead therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA, completing enrollment in this trial in mid-November," said Mai-Britt Zocca, president and CEO of IO Biotech. "The acceleration in enrollment observed in this study in the second half of 2023 is a testament to the need that exists today for more efficacious and better tolerated first-line treatment options for patients with advanced melanoma."
Stock_Titan
Posted - 1 month ago
$IOBT IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
https://www.stocktitan.net/news/IOBT/io-biotech-announces-2023-fourth-quarter-and-year-end-wbcg0jdbcwa3.html
